Medical imaging is among the most important innovations of our times, but modern healthcare asks more from it than ever before.
Misclassification rates resulting in over- and under-diagnosis are too high in cardiology and oncology, driving costs. This uncertainty makes it even harder to measure change reliably, one of the requirements for the use of imaging in personalized medicine. Successive rounds of hardware innovations produce ever bigger data sets, ever richer – but which challenge unaided interpretation.
What would it look like to better align medical imaging to the goals of outcome-based reimbursement models needed by Accountable Care Organizations? To scale well to address the needs of integrated delivery networks?
Elucid Bioimaging addresses these needs using its patented, multi-modality, Computer-Aided Phenotyping (CAP) Platform, first in cardiology and oncology, with potential beyond.
- National Science Foundation awards Elucid Bioimaging supplementary funding for integration of CAP with hospital IT systems., June 17, 2016
- Publication: Volumes Learned: It Takes More than Size to "Size Up" Pulmonary Lesions, Academic Radiology, June 6, 2016
- National Institutes of Health awards Elucid Bioimaging 2nd year of SBIR grant "vascuCAP: Non-invasive Computer-Aided Phenotyping of Vasculopathy., June 6, 2016
- Dr. Michael Rosol joins staff as Senior Director of Business Development. May 2016.
- Publication: Statistical Issues in Testing Conformance with the Quantitative Imaging Biomarker Alliance (QIBA) Profile Claims, Academic Radiology, April 2016
- Issued patent: Classification of Biological Tissue by Multi-Mode Data Registration, Segmentation, and Characterization. US Patent 9,235,887, issued January 12, 2016 (file date January 2013)
- Read More News...